Micro RNA – potential biomarkers in chronic kidney disease

Vladana Stojiljković; Nikola Stefanović; Marija Vukelić Nikolić; Branka Djordjević; Jelena Bašić; Gordana Kocić; Tatjana Cvetković

doi:10.5937/afmnai40-39805

Vladana Stojiljković Department of Biochemistry, Medical Faculty, University of Niš; University Clinical Center Niš
Nikola Stefanović Department of Pharmacy, Medical Faculty, University of Niš
Marija Vukelić Nikolić Department of Biology and human genetics, Medical Faculty, University of Niš
Branka Djordjević Department of Biochemistry, Medical Faculty, University of Niš
Jelena Bašić Department of Biochemistry, Medical Faculty, University of Niš
Gordana Kocić Department of Biochemistry, Medical Faculty, University of Niš
Tatjana Cvetković Department of Biochemistry, Medical Faculty, University of Niš, University Clinical Center Niš

DOI: https://doi.org/10.5937/afmnai40-39805

Abstract

Introduction: Standard biomarkers of diagnosis and follow-up of chronic kidney disease patients are appropriate neither in early diagnostics, adequate follow-up and progression assessment, nor in complication development risk assessment. For that reason, a search for new, more suitable biomarkers continues. Various studies suggested microRNAs as a potential solution, as they are involved in the pathogenesis of diabetic nephropathy, kidney cancer and kidney function impairment in general.

Methods: Internet search engines were used to find and select relevant literature data and electronic databases.

Results: Research published so far, in oncology especially, have reported various separate and panels of microRNAs as candidates for routine diagnostic implementation. Chronic kidney disease is, however, quite complex in terms of etiology of the disease occurrence, since there are many causes that can lead to kidney tissue damage and impairment of its function and finally full development of the chronic kidney disease. MicroRNAs are stable in bodily fluids, and hemodialysis procedure does not affect their levels. Also, high RNaze activity in chronic kidney disease patients does not accelerate microRNA degradation in their samples.

Conclusions: Literature data suggest microRNAs are appropriate candidates for diagnostic use in chronic kidney disease. However, there are challenges that are yet to be overcome in order to use microRNAs routinely.

References

Beltrami C, Simpson K, Jesky M, Wonnacott A, Carrington C, Holmans P, et al. Association of Elevated Urinary miR-126, miR-155, and miR-29b with Diabetic Kidney Disease. Am J Pathol. 2018 Sep;188(9):1982–92.

Bikbov B, Purcell CA, Levey AS, Smith M, Abdoli A, Abebe M, et al. Global, regional, and national burden of chronic kidney disease, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. The Lancet. 2020 Feb 29;395(10225):709–33.

Catalanotto C, Cogoni C, Zardo G. MicroRNA in Control of Gene Expression: An Overview of Nuclear Functions. Int J Mol Sci. 2016 Oct 13;17(10):E1712.

Cengiz M, Yavuzer S, Kılıçkıran Avcı B, Yürüyen M, Yavuzer H, Dikici SA, et al. Circulating miR-21 and eNOS in subclinical atherosclerosis in patients with hypertension. Clin Exp Hypertens. 2015 Nov 17;37(8):643–9.

Chau BN, Xin C, Hartner J, Ren S, Castano AP, Linn G, et al. MicroRNA-21 Promotes Fibrosis of the Kidney by Silencing Metabolic Pathways. Sci Transl Med. 2012 Feb 15;4(121):121ra18-121ra18.

Chen B. The miRNA-184 drives renal fibrosis by targeting HIF1AN in vitro and in vivo. Int Urol Nephrol. 2019 Mar 1;51(3):543–50.

Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008 Oct;18(10):997–1006.

Chu A, Robertson G, Brooks D, Mungall AJ, Birol I, Coope R, et al. Large-scale profiling of microRNAs for The Cancer Genome Atlas. Nucleic Acids Res. 2016 Jan 8;44(1):e3.

Chung ACK, Lan HY. Chemokines in renal injury. J Am Soc Nephrol JASN. 2011 May;22(5):802–9.

Cloonan N, Brown MK, Steptoe AL, Wani S, Chan WL, Forrest AR, et al. The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol. 2008 Aug 14;9(8):R127.

Cui C, Cui Y, Fu Y, Ma S, Zhang S. Microarray analysis reveals gene and microRNA signatures in diabetic kidney disease. Mol Med Rep. 2018 Feb;17(2):2161–8.

Czech B, Hannon GJ. Small RNA sorting: matchmaking for Argonautes. Nat Rev Genet. 2011 Jan;12(1):19–31.

Feng J, Li A, Deng J, Yang Y, Dang L, Ye Y, et al. miR-21 attenuates lipopolysaccharide-induced lipid accumulation and inflammatory response: potential role in cerebrovascular disease. Lipids Health Dis. 2014 Feb 7;13(1):27.

Franczyk B, Gluba-Brzózka A, Olszewski R, Parolczyk M, Rysz-Górzyńska M, Rysz J. miRNA biomarkers in renal disease. Int Urol Nephrol. 2022 Mar;54(3):575–88.

Griffiths-Jones S. The microRNA Registry. Nucleic Acids Res. 2004 Jan 1;32(90001):109D – 111.

He W, Zhuang J, Zhao ZG, Luo H, Zhang J. miR-328 prevents renal fibrogenesis by directly targeting TGF-β2. Bratisl Lek Listy. 2018;119(7):434–40.

He X, Liao S, Lu D, Zhang F, Sun Y, Wu Y. MiR-125b promotes migration and invasion by targeting the vitamin D receptor in renal cell carcinoma. Int J Med Sci. 2021;18(1):150–6.

Hunter MP, Ismail N, Zhang X, Aguda BD, Lee EJ, Yu L, et al. Detection of microRNA expression in human peripheral blood microvesicles. PloS One. 2008;3(11):e3694.

Iwano M, Neilson EG. Mechanisms of tubulointerstitial fibrosis. Curr Opin Nephrol Hypertens. 2004 May;13(3):279–84.

Jha V, Garcia-Garcia G, Iseki K, Li Z, Naicker S, Plattner B, et al. Chronic kidney disease: global dimension and perspectives. Lancet Lond Engl. 2013 Jul 20;382(9888):260–72.

Jin J, Ku YH, Kim Y, Kim Y, Kim K, Lee JY, et al. Differential Proteome Profiling Using iTRAQ in Microalbuminuric and Normoalbuminuric Type 2 Diabetic Patients. Exp Diabetes Res. 2012;2012:168602.

KDIGO_2012_CKD_GL.pdf [Internet]. [cited 2022 Jun 1]. Available from: https://kdigo.org/wp-content/uploads/2017/02/KDIGO_2012_CKD_GL.pdf

Kida K, Nakajima M, Mohri T, Oda Y, Takagi S, Fukami T, et al. PPARα Is Regulated by miR-21 and miR-27b in Human Liver. Pharm Res. 2011 Oct 1;28(10):2467–76.

Kozomara A, Birgaoanu M, Griffiths-Jones S. miRBase: from microRNA sequences to function. Nucleic Acids Res. 2019 Jan 8;47(D1):D155–62.

Kumarswamy R, Volkmann I, Jazbutyte V, Dangwal S, Park DH, Thum T. Transforming Growth Factor-β–Induced Endothelial-to-Mesenchymal Transition Is Partly Mediated by MicroRNA-21. Arterioscler Thromb Vasc Biol. 2012 Feb;32(2):361–9.

Kumarswamy R, Volkmann I, Thum T. Regulation and function of miRNA-21 in health and disease. RNA Biol. 2011 Sep 1;8(5):706–13.

Levey AS, Coresh J. Chronic kidney disease. Lancet Lond Engl. 2012 Jan 14;379(9811):165–80.

Li H, Zhang X, Wang F, Zhou L, Yin Z, Fan J, et al. MicroRNA-21 Lowers Blood Pressure in Spontaneous Hypertensive Rats by Upregulating Mitochondrial Translation. Circulation. 2016 Sep 6;134(10):734–51.

Martino F, Lorenzen J, Schmidt J, Schmidt M, Broll M, Görzig Y, et al. Circulating MicroRNAs Are Not Eliminated by Hemodialysis. PLOS ONE. 2012 Jun 8;7(6):e38269.

Meng J, Li L, Zhao Y, Zhou Z, Zhang M, Li D, et al. MicroRNA-196a/b Mitigate Renal Fibrosis by Targeting TGF-β Receptor 2. J Am Soc Nephrol JASN. 2016 Oct;27(10):3006–21.

Miyoshi K, Miyoshi T, Siomi H. Many ways to generate microRNA-like small RNAs: non-canonical pathways for microRNA production. Mol Genet Genomics MGG. 2010 Aug;284(2):95–103.

Mogilyansky E, Rigoutsos I. The miR-17/92 cluster: a comprehensive update on its genomics, genetics, functions and increasingly important and numerous roles in health and disease. Cell Death Differ. 2013 Dec;20(12):1603–14.

Muendlein A, Geiger K, Leiherer A, Saely CH, Fraunberger P, Drexel H. Evaluation of the associations between circulating microRNAs and kidney function in coronary angiography patients. Am J Physiol-Ren Physiol. 2020 Feb;318(2):F315–21.

Mukhadi S, Hull R, Mbita Z, Dlamini Z. The Role of MicroRNAs in Kidney Disease. Non-Coding RNA. 2015 Nov 18;1(3):192–221.

Neal CS, Michael MZ, Pimlott LK, Yong TY, Li JYZ, Gleadle JM. Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant. 2011 Nov 1;26(11):3794–802.

Ramanathan K, Padmanabhan G. MiRNAs as potential biomarker of kidney diseases: A review. Cell Biochem Funct. 2020;38(8):990–1005.

Sayilar E. Biomarker Potential of Urine miR-451 at Different Stages of Diabetic Nephropathy. J Diabetes Metab. 2016 Jan 1;07.

Théry C. Exosomes: secreted vesicles and intercellular communications. F1000 Biol Rep. 2011 Jul 1;3:15.

Tomino Y. Pathogenesis and treatment of chronic kidney disease: a review of our recent basic and clinical data. Kidney Blood Press Res. 2014;39(5):450–89.

Vanholder R, Group (EUTox) for the EUTW, Massy Z, Group (EUTox) for the EUTW, Argiles A, Group (EUTox) for the EUTW, et al. Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant. 2005 Jun 1;20(6):1048–56.

Vester B, Wengel J. LNA (locked nucleic acid): high-affinity targeting of complementary RNA and DNA. Biochemistry. 2004 Oct 26;43(42):13233–41.

Volume 2: ESRD in the United States. 2018;2:412.

Wald R, Yan AT, Perl J, Jiang D, Donnelly MS, Leong-Poi H, et al. Regression of left ventricular mass following conversion from conventional hemodialysis to thrice weekly in-centre nocturnal hemodialysis. BMC Nephrol. 2012 Dec;13(1):3.

Wang Y, Zheng ZJ, Jia YJ, Yang YL, Xue YM. Role of p53/miR-155-5p/sirt1 loop in renal tubular injury of diabetic kidney disease. J Transl Med. 2018 May 30;16(1):146.

Wong RKY, MacMahon M, Woodside JV, Simpson DA. A comparison of RNA extraction and sequencing protocols for detection of small RNAs in plasma. BMC Genomics. 2019 Jun 3;20(1):446.

Yang JS, Phillips MD, Betel D, Mu P, Ventura A, Siepel AC, et al. Widespread regulatory activity of vertebrate microRNA* species. RNA. 2011 Feb;17(2):312–26.

Ying G, Wu R, Xia M, Fei X, He QE, Zha C, et al. Identification of eight key miRNAs associated with renal cell carcinoma: A meta-analysis. Oncol Lett. 2018 Nov;16(5):5847–55.

Zhang Z, Peng H, Chen J, Chen X, Han F, Xu X, et al. MicroRNA-21 protects from mesangial cell proliferation induced by diabetic nephropathy in db/db mice. FEBS Lett. 2009 Jun 18;583(12):2009–14.